Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment - GBI Research Reports

Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment

Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment - GBI Research Reports
Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
Published Apr 01, 2011
130 pages — Published Apr 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest report, Biosimilars Approval Pathways in the US and Europe Development and Approval of Biosimilar mAbs May Face Tough Regulatory Environment that provides key data, information and analysis of the major trends and issues affecting the global biosimilar market. The report provides a comprehensive insight into the biosimilar market. It offers geography-wise as well as category-wise market forecasts for biosimilars and provides the drivers and restraints affecting the biosimilars market. The report also talks about the business environment and the key success factors in the global biosimilar industry. The report also describes the regulatory environment in the US, top five European markets and Japan with respect to biosimilars. At the end, the report looks into the competitive landscape of the biosimilar industry by offering profiles of key players in the industry and the analysis of major deals that took place in the industry.

Scope

The report covers -
- Data and analysis on the biosimilar market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Market forecast for global biosimilar market from 2009 to 2016, geography-wise as well as product category-wise.
- Key drivers and restraints that have had a significant impact on the market globally as well as at national level.
- The regulatory environment for biosimilars in the US, the EU and in Japan.
- Analysis of competitive environment in the industry, profiles of key players in the biosimilar market. The companies studied in this report are Sandoz, Teva Pharmaceuticals, Hospira, Dr. Reddys, Biocon, Watson Pharmaceuticals, Biopartners, Reliance Life Sciences, Stada, Intas, Celltrion and 3S Bio.
- Key M&A activities and Licensing Agreements that took place between 2008 and 2010 in the global biosimilar market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to -
- Make more informed business decisions from the insightful and in-depth analysis of the global biosimilar market and the factors shaping it.
- Identify the key areas of deal making through thorough understanding of the deals landscape in the global biosimilar market.
- Build effective strategies to launch the pipeline products by identifying potential geographies.
- Identify the companies from emerging nations for collaborations along with their key capabilities.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill your portfolio gaps.

  
Source:
Document ID
GBIHC075MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents37
  List of Tables61
  List of Figures73
Biosimilars Approval Pathways in the US and Europe Introduction101
  GBI Research Report Guidance101
Biosimilars Approval Pathways in the US and Europe Market Overview1115
  Overview of the Biopharmaceutical Industry118
  Biosimilars and their Significance193
  Comparison of Biosimilars with Generics222
  Biopharmaceutical Manufacturing Process242
Biosimilars Approval Pathways in the US and Europe Market Characterization2619
  Global Biosimilar Market Size and Forecast261
  The US Biosimilars Market Size and Forecast271
  Europe Biosimilar Market Size and Forecast282
  Japan Biosimilars Market Size and Forecasts301
  Market Forecasts for Biosimilars311
    Human Growth Hormone (hGH) Biosimilars Markets312
    Erythropoietin (EPO) Biosimilars Markets332
    Granulocyte Colony Stimulating Factor (G-CSF) Biosimilars Markets352
  Opportunity Analysis371
    Interferon alfa Biosimilars371
    Interferon beta Biosimilars382
    Insulin and Insulin Analogs Biosimilars402
    TNF alfa Inhibitor Biosimilars421
    Biosimilars for Monoclonal Antibodies against Cancer432
Biosimilars Approval Pathways in the US and Europe Industry Dynamics456
  Key Success Factors in the Biosimilar Industry451
    Long Term Strategy451
    Sound Financial Structure461
    Comprehensive Competitive Intelligence461
    Biomanufacturing Competencies461
    Clinical Development and Regulatory Expertise461
    Marketing, Sales and Distribution Capabilities461
  Participants in the Biosimilar Industry471
  Suppliers481
    Clinical Trial Capability Providers481
    Manufacturing Capacity Providers481
    Media and Reagents Providers481
  Innovators491
  Stakeholders491
    Regulators491
    Payers491
    Physicians501
    Patients and Patient Groups501
Biosimilars Approval Pathways in the US and Europe Drivers and Restraints518
  Drivers521
    Need to Cut Healthcare Costs in Developed Economies522
    Lower Development Costs and Regulatory Costs Compared to a New Biologic Drug541
    Lower Overall Cost of Treatment Using Biosimilar Drugs Compared to Biologics551
    Patent Expiry for Blockbuster Biologics551
    Increasing Uptake of Biologic Drugs561
    More Profitable than Generic Drugs561
  Restraints561
    Absence of Automatic Substitution561
    Higher Development and Manufacturing Costs Compared to Generics571
    High Entry Barriers581
    Threat from Second Generation Biologic Drugs581
    Patent Protection Around Biologic Drugs581
Biosimilars Approval Pathways in the US and Europe Regulatory Landscape5938
  Regulatory Landscape in the US601
    Regulatory Framework for Biopharmaceutical Industry602
    Evolution of Regulatory Pathways for Biosimilars623
    BPCIA and the Pathway for Approval of Biosimilar Products651
      Biosimilarity and Interchangeability651
      FDA Guidelines for Approval and Regulation of Biosimilars651
      Data Requirement651
      Market and Data Exclusivity661
      Patent Dispute Resolution Procedure662
      Notice of Commercial Marketing681
      Closure of the FD&C 505(b) approval pathway for biologics691
      Substitution is a Decision Taken at Local Level691
  FDA s Public Meeting on Biosimilars701
    Data requirement to Demonstrate Biosimilarity711
    The Standard for Interchangeability711
    Naming for Biosimilars711
    Extrapolation711
    Foreign Studies711
    Other Issues711
    Drivers and Barriers721
  Regulatory Landscape in Europe731
    Regulatory Framework for Biopharmaceutical Industry731
    Evolution of Regulatory Pathways for Biosimilars741
    Current Position on Biosimilars751
      Overarching Guidelines761
      Quality Guidelines771
      Non Clinical and Clinical Guidelines771
      Annexes Product Specific Guidelines771
      Post Authorization Requirements781
      Data Exclusivity Period791
      What does this mean to the Biosimilar Industry?801
    The Bolar Type Provision801
    The Comparability Exercise811
    Biosimilars Approvals and Applications822
    EMEA Guidelines for Biosimilar mAb841
    Issues Facing the European Biosimilars Industry841
      Naming841
      Labeling851
      Substitution/Interchangeability851
      Pharmacovigilance851
    Drivers for the European Biosimilars Market851
      Patent Expiry of Key Biologic Drugs Will Boost the Market Potential861
      Biosimilars Will Be Widely Accepted by Payers as Means to Reduce Rising Healthcare Costs861
      Leading Pharma Companies Eye Biosimilars as an Area of Growth861
      Biosimilar Manufacturers from Low Cost Emerging Countries Will Drive Market Expansion861
    Barriers for the European Biosimilars Market861
      Substitution Still Remains a Contentious Issue in Many European Countries861
      Barriers to Entry Remain High Due to a Complex and High Cost Manufacturing Process861
      Trade-off Between Patient Safety and Healthcare Costs Will Resist the Acceptance of Biosimilars871
    Country Analysis The UK871
      Structure of the Healthcare System871
      Pricing and Reimbursement Mechanisms871
      Drivers and Barriers for Biosimilars881
    Country Analysis Germany881
      Structure of the Healthcare System881
      Pricing and Reimbursement Mechanisms891
      Drivers and Barriers for Biosimilars891
    Country Analysis France901
      Structure of the Healthcare System901
      Pricing and Reimbursement Mechanisms901
      Drivers and Barriers for Biosimilars911
    Country Analysis Spain911
      Structure of the Healthcare System911
      Pricing and Reimbursement Mechanisms911
      Drivers and Barriers for Biosimilars921
    Country Analysis Italy931
      Structure of the Healthcare System931
      Pricing and Reimbursement Mechanisms931
      Drivers and Barriers for Biosimilars931
  Regulatory Landscape in Japan941
    Regulatory Framework for Biopharmaceutical Industry941
    Evolution of Regulatory Pathways for Biosimilars941
    Current Position on Biosimilars951
      Approved Biosimilars951
    Drivers and Barriers961
Biosimilars Approval Pathways in the US and Europe Competitive Landscape9725
  Profiles of Major Biosimilar Players971
    Sandoz971
      Approved Biosimilar Products:981
      Financial Performance991
    Teva Pharmaceuticals Ltd1001
      Approved Biosimilars1001
      Pipeline Products1011
      Financial Performance1011
    Hospira Inc1021
      Approved Biosimilar Products:1021
      Pipeline1022
    Dr. Reddy s Laboratories1041
      Approved Biosimilars1051
    Biocon Ltd1061
      Approved biosimilar products:1071
      Pipeline1071
    Biopartners1081
      Approved Biosimilars1091
    Watson Pharmaceuticals1101
      Financial Performance1101
      Pipeline1111
    STADA Arzneimittel AG1121
      Approved and Pipeline Biosimilar Products1131
    Reliance Life Sciences1141
      Approved Biosimilar products1151
    Intas Biopharmaceuticals1162
    Celltrion Inc.1181
      Pipeline1191
    3SBio Inc.1201
      Approved Biosimilars1201
      Pipeline Products1211
Biosimilars Approval Pathways in the US and Europe Strategic Consolidations1223
  M&A Deals1221
    Pfizer Biocon Deal1221
    Teva Acquired Ratiopharm1221
    Watson Itero Deal1221
    Biocon and Mylan Strategic Collaboration1221
    Merck Acquired Insmed s Follow-On Biologics for $130m1221
    Teva and Lonza JV Targets Biosimilars1231
    GTC Enters Follow-On-Biologic Founder Development Collaboration with Ag Research1231
    Apotex Intas Deal1231
    Teva Acquires CoGenesys1231
  R&D Licensing Deals1241
    Innogene Seals Deal With CIMAB to Market Biosimilars1241
    Abraxis Licenses Rights to Biosimilar from Indian Firm Biocon1241
Biosimilars Approval Pathways in the US and Europe Appendix1256
  Market Definitions1251
  Abbreviations1262
  Research Methodology1282
    Coverage1281
    Secondary Research1281
    Primary Research1291
    Expert Panel Validation1291
  Contact Us1291
  Sources1301
  Disclaimer1301

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment" Apr 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Biosimilars-Approval-Pathways-in-the-US-and-Europe-Development-and-Approval-of-Biosimilar-mABs-May-Face-Tough-Regulatory-Environment-2115-186>
  
APA:
GBI Research Reports. (2011). Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment Apr 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Biosimilars-Approval-Pathways-in-the-US-and-Europe-Development-and-Approval-of-Biosimilar-mABs-May-Face-Tough-Regulatory-Environment-2115-186>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.